Erik Hertervig

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

Gunnar Järnerot, Erik Hertervig, Ingalill Friis–Liby et al. · Gastroenterology · 2005 · 1.1K citations · Full text

Pharmacy, Immunology, Pharmacotherapy +15

Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease

Ryan C. Ungaro, Clara Yzet, Peter Bossuyt et al. · Gastroenterology · 2020 · 238 citations · Full text

Veterinary Medicine, Clinical Sciences, Immunology +13

Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis

Viktoria Bergqvist, Erik Hertervig, Peter Gedeon et al. · Cancer Immunology Immunotherapy · 2017 · 236 citations · Full text

Life Sciences, Immunology, Oncology +17

Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study

A. Gustavsson, G Järnerot, Erik Hertervig et al. · Alimentary Pharmacology & Therapeutics · 2010 · 180 citations

Pharmacy, Pharmacotherapy, Surgery +12

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

Carl Eriksson, Jan Marsal, Daniel Bergemalm et al. · Scandinavian Journal of Gastroenterology · 2017 · 124 citations

Medicine, Clinical Sciences, Pharmacotherapy +15